Literature DB >> 9635593

Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors.

J C Luo1, S Yamaguchi, A Shinkai, K Shitara, M Shibuya.   

Abstract

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is believed to be a potent mediator of peritoneal fluid accumulation and angiogenesis and of tumor growth in ascites tumor. Such roles, however, have not been generally established because of insufficient quantitative and systemic analyses. To address this, we examined the expression of VEGF in 13 mouse ascites tumors (5 sarcomas, 3 carcinomas, 2 lymphomas, 1 leukemia, 1 mastocytoma, and 1 plasmacytoma). Using a newly developed sensitive and specific radioreceptor binding assay and functional assays, we found that active VEGF was significantly accumulated (6-850 ng/ml) in the ascites fluids of all 13 tumors. VEGF concentrations are higher in the tumors of sarcoma and carcinoma origin (430.4 +/- 234.2 ng/ml) than in those of lymphoma and hematological tumor origin (19.2 +/- 10.45 ng/ml). VEGF that accumulated in the peritoneal fluids or expressed in the ascites tumor cells was easily visualized with immunoprecipitation Western blot analysis with a rough correlation to the expression levels of VEGF gene in these tumor cells, suggesting that the tumor cells, at least in part, contributed to the production of the VEGF that accumulated in the ascites fluid. Most ascites tumors expressed VEGF; the 164-amino acid isoform was predominant, the 120-amino acid isoform was less abundant, and the 188-amino acid isoform was least abundant. Several representative ascites tumors expressed similar, if not higher, levels of VEGF when they were cultured at normoxic states, suggesting that they expressed VEGF at high levels in a constitutive manner. The microvessel densities in the peritoneal walls of tumor-bearing mice, which are significantly higher than those in normal mice, basically correlated to but did not parallel the VEGF concentrations in their respective ascites fluids. Thus, a complicated relationship may exist between the VEGF production and angiogenesis associated with ascites tumor in vivo. Taken together, our observations suggest that VEGF plays a fundamental role in ascites tumor formation; however, its importance may vary according to tumor origin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635593

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization.

Authors:  Ming Zhang; Dechao Yu; Chun Yang; Qingjie Xia; Wang Li; Bin Liu; Hong Li
Journal:  Pharm Res       Date:  2008-10-15       Impact factor: 4.200

2.  Shp2 suppresses PyMT-induced transformation in mouse fibroblasts by inhibiting Stat3 activity.

Authors:  Ying Yang; Beibei Jiang; Yingqing Huo; Luca Primo; Jean S Dahl; Thomas L Benjamin; Jincai Luo
Journal:  Virology       Date:  2010-11-05       Impact factor: 3.616

3.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

4.  Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Authors:  Robert A Burger
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

5.  Antiangiogenic effect of 2-benzoyl-phenoxy acetamide in EAT cell is mediated by HIF-1alpha and down regulation of VEGF of in-vivo.

Authors:  B T Prabhakar; Shaukath Ara Khanum; S Shashikanth; Bharathi P Salimath
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

6.  Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice.

Authors:  Sachie Hiratsuka; Kazuki Nakao; Kenji Nakamura; Motoya Katsuki; Yoshiro Maru; Masabumi Shibuya
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

7.  Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos.

Authors:  Sachie Hiratsuka; Yuki Kataoka; Kazuki Nakao; Kenji Nakamura; Shunichi Morikawa; Satoshi Tanaka; Motoya Katsuki; Yoshiro Maru; Masabumi Shibuya
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

8.  Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.

Authors:  H Kanayama; S Yano; S J Kim; S Ozawa; L M Ellis; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

9.  Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model.

Authors:  Hong Young Jun; Hong-Hua Yin; Sun-Hee Kim; Seong Hoon Park; Hun Soo Kim; Kwon-Ha Yoon
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

10.  Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Authors:  James S Ferriss; James J Java; Michael A Bookman; Gini F Fleming; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew P Boente; Robert A Burger
Journal:  Gynecol Oncol       Date:  2015-07-26       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.